FORE Biotherapeutics Receives First-Ever Breakthrough Therapy Designation for High-Grade Glioma Targeted Therapy
核心洞察
The FDA has granted Breakthrough Therapy Designation to plixorafenib for treating adult patients with BRAF V600E (搜索)-mutated high-grade glioma (搜索), marking the first such designation for a targeted therapy in this indication.
The designation is based on promising data from approximately 25 patients showing a 67% overall response rate in MAPK inhibitor-naive patients with BRAF (搜索) V600-mutated primary CNS tumors (搜索).
Plixorafenib is a novel BRAF (搜索) inhibitor with a unique dimer-breaking mechanism that has demonstrated favorable safety and tolerability compared to existing BRAF inhibitors.
FORE Biotherapeutics (搜索) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to plixorafenib for the treatment of adult patients with BRAF V600E (搜索)-mutated high-grade glioma (搜索) (HGG). The company believes this represents the first Breakthrough Therapy Designation granted to a targeted therapy for high-grade glioma, a significant milestone for patients facing this aggressive brain cancer.
The FDA's decision was based on data from approximately 25 patients treated in a completed Phase 1/2a clinical trial and the ongoing Phase 2 FORTE basket study evaluating plixorafenib in BRAF V600E (搜索)-mutated central nervous system tumors. The designation recognizes plixorafenib's potential to provide substantial improvement over available therapies for this serious condition.
Clinical Efficacy and Safety Profile
Data from the Phase 1/2a trial, previously presented at ASCO 2023 and SNO 2023, demonstrated that plixorafenib achieved a 67% overall response rate in a pre-specified subgroup of patients with refractory MAPK inhibitor-naive BRAF (搜索) V600-mutated primary CNS tumors (搜索). The drug showed robust anti-tumor activity supported by duration of response and clinical benefit rate across BRAF-altered tumor types and CNS histologies.
In patients with V600 alterations who were MAPK inhibitor-naive, plixorafenib achieved a 42% response rate with a median duration of response of 17.8 months and a clinical benefit rate exceeding 70%. The drug demonstrated a favorable safety and tolerability profile across tumor types, with a discontinuation rate due to drug-related adverse events of less than 2%.
"High-grade gliomas are aggressive primary brain tumors (搜索) associated with poor outcomes despite multimodality treatment approaches," said Dr. Macarena de la Fuente, Chief of the Neuro-Oncology Division at the University of Miami Miller School of Medicine. "In addition to their limited prognosis, patients experience substantial morbidity related to both the disease itself and the toxicities of current therapies. Therefore, there remains a critical need for novel treatments that are not only effective but also better tolerated."
Novel Mechanism of Action
Plixorafenib is a novel BRAF (搜索) inhibitor that functions as both a dimer and paradox breaker, with high selectivity for BRAF alterations. This unique mechanism of action is designed to overcome the limitations of earlier generation BRAF inhibitors that led to rapid disease recurrence and required combination with MEK (搜索) inhibitors.
"The granting of Breakthrough Therapy Designation is a significant development milestone for plixorafenib and reinforces our conviction in its unique mechanism of action," said Dr. Stacie Peacock Shepherd, Chief Medical Officer of FORE Biotherapeutics (搜索). "BRAF (搜索) alterations are an important actionable driver in the molecularly integrated clinical decision paradigm for the treatment of high-grade gliomas, and plixorafenib has demonstrated a differentiated profile in patients with primary CNS tumors (搜索), including glioblastoma (搜索) and other high-grade gliomas."
Regulatory Pathway and Timeline
The Breakthrough Therapy Designation adds to plixorafenib's existing regulatory recognitions, including Fast Track Designation for cancers harboring BRAF (搜索) Class 1 and Class 2 alterations and Orphan Drug Designation for primary brain and CNS malignancies. The BTD provides FORE Biotherapeutics (搜索) with more frequent FDA guidance, involvement of senior reviewers, and eligibility for rolling and priority review of the marketing application.
FORE Biotherapeutics (搜索) expects topline results from the FORTE basket trial evaluating plixorafenib monotherapy for recurrent or progressive BRAF (搜索) V600 primary CNS tumors (搜索) by the end of 2026. The company believes that positive results from this CNS basket would support submission of a New Drug Application under the FDA's Accelerated Approval pathway.
FORTE Basket Study Design
The registration-intended FORTE Master Protocol is a global Phase 2 clinical trial including four sub-protocol baskets evaluating plixorafenib in distinct patient populations. The three monotherapy indications currently under evaluation are recurrent or progressive BRAF (搜索) V600 primary CNS tumors (搜索), solid tumors with BRAF fusions, and rare BRAF V600 mutated solid tumors.
As part of the Bayesian adaptive design, interim efficacy analyses are conducted in each basket. The company reported a positive outcome from the BRAF (搜索) V600 CNS basket in the third quarter of 2025, with the Independent Data Monitoring Committee supporting continuation of the study based on responses assessed by blinded independent central review.